A comparison of cisplatin and fluorouracil alone or with docetaxel in squamous cell carcinoma of the head and neck: Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 6, 2008, Pages 306-307

  Ho, Kean ^a   Slevin, Nick ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; INOPERABLE CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 44649124517     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1129     Document Type: Short Survey

References (3)

1. Pignon JP et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955
2. Vermorken JB et al. (2007) Cisplatin; fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704
3. Hitt R et al. (2006) Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol (2006 ASCO Annual Meeting Proceedings [Post-Meeting Edition]) 24 Suppl): AS5515